241 related articles for article (PubMed ID: 36720496)
21. Transmembrane tumor necrosis factor-alpha sensitizes adipocytes to insulin.
Zhou W; Yang P; Liu L; Zheng S; Zeng Q; Liang H; Zhu Y; Zhang Z; Wang J; Yin B; Gong F; Wu Y; Li Z
Mol Cell Endocrinol; 2015 May; 406():78-86. PubMed ID: 25725372
[TBL] [Abstract][Full Text] [Related]
22. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
23. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
24. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
Cha JH; Chan LC; Wang YN; Chu YY; Wang CH; Lee HH; Xia W; Shyu WC; Liu SP; Yao J; Chang CW; Cheng FR; Liu J; Lim SO; Hsu JL; Yang WH; Hortobagyi GN; Lin C; Yang L; Yu D; Jeng LB; Hung MC
J Biol Chem; 2022 Apr; 298(4):101817. PubMed ID: 35278434
[TBL] [Abstract][Full Text] [Related]
25. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
26. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
Xia W; Chen J; Hou W; Chen J; Xiong Y; Li H; Qi X; Xu H; Xie Z; Li M; Zhang X; Li J
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047817
[TBL] [Abstract][Full Text] [Related]
27. Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade.
Song H; Wang H; Gong M; Wu L; Liu X; Cao W; Gao X; Dou R; Chen Q; Hu H
Cell Biol Int; 2022 Feb; 46(2):278-287. PubMed ID: 34854515
[TBL] [Abstract][Full Text] [Related]
28. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
[TBL] [Abstract][Full Text] [Related]
29. Transmembrane TNF-alpha mediates "forward" and "reverse" signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells.
Zhang H; Yan D; Shi X; Liang H; Pang Y; Qin N; Chen H; Wang J; Yin B; Jiang X; Feng W; Zhang W; Zhou M; Li Z
J Leukoc Biol; 2008 Sep; 84(3):789-97. PubMed ID: 18550789
[TBL] [Abstract][Full Text] [Related]
30. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
31. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
32. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.
Zhou M; Chen M; Shi B; Di S; Sun R; Jiang H; Li Z
Mol Ther; 2022 Nov; 30(11):3379-3393. PubMed ID: 35927951
[TBL] [Abstract][Full Text] [Related]
33. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
34. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
Zhang Z; Lin G; Yan Y; Li X; Hu Y; Wang J; Yin B; Wu Y; Li Z; Yang XP
Oncogene; 2018 Jun; 37(25):3456-3470. PubMed ID: 29559745
[TBL] [Abstract][Full Text] [Related]
35. Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2.
Miao K; Zhou L; Ba H; Li C; Gu H; Yin B; Wang J; Yang XP; Li Z; Wang DW
PLoS Biol; 2020 Dec; 18(12):e3000967. PubMed ID: 33270628
[TBL] [Abstract][Full Text] [Related]
36. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
[TBL] [Abstract][Full Text] [Related]
37. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
38. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
40. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
